| CME Provider |
Website title |
Module | CME
credits |
Expiry |
|
Academic Medical Center Amsterdam. Dept Vascular Medicine |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
5 Things a cardiologist needs to know about diabetes - https://pace-cmelearninglab.coursepath.com/1509890/course-toc |
HbA1c in CVD |
0 |
04 Jun 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
5 Things a cardiologist needs to know about diabetes - https://pace-cmelearninglab.coursepath.com/1509890/course-toc |
Hypoglycemia in CV medicine - why worry? |
0 |
04 Jun 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
5 Things a cardiologist needs to know about diabetes - https://pace-cmelearninglab.coursepath.com/1509890/course-toc |
Key classes of antidiabetic drugs |
0 |
04 Jun 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
5 Things a cardiologist needs to know about diabetes - https://pace-cmelearninglab.coursepath.com/1509890/course-toc |
Natural history of diabetes: focus on microvascular and macrovascular complications |
1 |
04 Jun 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
5 Things a cardiologist needs to know about diabetes - https://pace-cmelearninglab.coursepath.com/1509890/course-toc |
T2DM and CV outcomes |
0 |
04 Jun 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Clinical updates in management of cardiovascular risk - https://academy1745879297.coursepath.com/1706498/course-toc |
Early intervention for lifetime CV risk reduction |
1 |
07 Aug 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Clinical updates in management of cardiovascular risk - https://academy1745879297.coursepath.com/1706498/course-toc |
Estimating CV risk and treatment benefit |
0 |
07 Aug 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Clinical updates in management of cardiovascular risk - https://academy1745879297.coursepath.com/1706498/course-toc |
Importance of hypertension in CVD prevention |
0 |
07 Aug 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Clinical updates in management of cardiovascular risk - https://academy1745879297.coursepath.com/1706498/course-toc |
The role of lipids in CVD prevention: Lessons learned about statins |
0 |
07 Aug 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Contemporary management of a patient with heart failure and diabetes: Implications from recent trials - https://pace-cmelearninglab.coursepath.com/1968642/course-toc |
Current management of heart failure & T2DM |
1 |
19 Sep 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Contemporary management of a patient with heart failure and diabetes: Implications from recent trials - https://pace-cmelearninglab.coursepath.com/1968642/course-toc |
Guidance from outcome trials: What are the clinical implications |
0 |
19 Sep 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Contemporary management of a patient with heart failure and diabetes: Implications from recent trials - https://pace-cmelearninglab.coursepath.com/1968642/course-toc |
Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology |
0 |
19 Sep 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Contemporary management of a patient with heart failure and diabetes: Implications from recent trials - https://pace-cmelearninglab.coursepath.com/1968642/course-toc |
Understanding the mechanisms of SGLT2 inhibition in heart failure and diabetes |
0 |
19 Sep 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Diabetic Kidney Disease: Exploring mechanisms and outcomes of SGLT2 inhibition - https://pace-cmelearninglab.coursepath.com/2099714/course-toc |
Addressing the remaining questions on SGLT2 & CKD: A review of new outcome trials |
0 |
07 Dec 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Diabetic Kidney Disease: Exploring mechanisms and outcomes of SGLT2 inhibition - https://pace-cmelearninglab.coursepath.com/2099714/course-toc |
SGLT2 inhibition in kidney disease: What are the key lessons from the EMPA-REG OUTCOME trial? |
1 |
07 Dec 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Diabetic Kidney Disease: Exploring mechanisms and outcomes of SGLT2 inhibition - https://pace-cmelearninglab.coursepath.com/2099714/course-toc |
Understanding CKD & SGLT2 inhibition: What are the key mechanisms for benefit? |
0 |
07 Dec 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Exploring the role of GLP-1 RA in the management of CVD & T2DM - https://pace-cmelearninglab.coursepath.com/1837570/course-toc |
Clinical trials in diabetes and CVD - What did we learn? |
0 |
10 Dec 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Exploring the role of GLP-1 RA in the management of CVD & T2DM - https://pace-cmelearninglab.coursepath.com/1837570/course-toc |
Novel diabetes drugs in clinical management: extending the opportunities |
0 |
10 Dec 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Exploring the role of GLP-1 RA in the management of CVD & T2DM - https://pace-cmelearninglab.coursepath.com/1837570/course-toc |
Translation of novel approaches in CVD & diabetes to clinical practice |
0 |
10 Dec 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Exploring the role of GLP-1 RA in the management of CVD & T2DM - https://pace-cmelearninglab.coursepath.com/1837570/course-toc |
What are the key mechanisms of CV benefit of novel diabetes drugs? |
0 |
10 Dec 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Exploring the role of GLP-1 RA in the management of CVD & T2DM - https://pace-cmelearninglab.coursepath.com/1837570/course-toc |
What is the science driving CVD and T2DM? |
1 |
10 Dec 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Managing Diabetes & CVD: Is epigenetics a new way forward? - https://academy1745879297.coursepath.com/my-courses |
Insights from the first trials in epigenetics in human: What is the way forward? |
1 |
24 Jan 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Managing Diabetes & CVD: Is epigenetics a new way forward? - https://academy1745879297.coursepath.com/my-courses |
Managing high risk diabetes patient with cardiovascular disease: What works, and what else can we do? |
1 |
24 Jan 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Managing Diabetes & CVD: Is epigenetics a new way forward? - https://academy1745879297.coursepath.com/my-courses |
Promise of epigenetic modulation as a target in atherosclerotic patients. |
1 |
24 Jan 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure - https://academy1745879297.coursepath.com/my-courses |
Heart failure & Diabetes: Time for a more unified approach |
1 |
09 Dec 2019 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure - https://academy1745879297.coursepath.com/my-courses |
Management of CV Risk & T2DM: Implications of novel outcome trials |
1 |
09 Dec 2019 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure - https://academy1745879297.coursepath.com/my-courses |
SGLT2 inhibition in cardiology: What a cardiologist needs to know |
1 |
09 Dec 2019 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Novel concepts and treatments of comorbidities in heart failure with preserved ejection fraction - https://pace-cmelearninglab.coursepath.com/1903106/course-toc |
Atrial fibrillation & HFpEF: Novel device and therapeutic approaches |
0 |
19 Sep 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Novel concepts and treatments of comorbidities in heart failure with preserved ejection fraction - https://pace-cmelearninglab.coursepath.com/1903106/course-toc |
Diabetes & Obesity in HFpEF: New targets in heart failure management |
0 |
19 Sep 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Novel concepts and treatments of comorbidities in heart failure with preserved ejection fraction - https://pace-cmelearninglab.coursepath.com/1903106/course-toc |
HFpEF: from understanding the physiology to development of new treatments |
1 |
19 Sep 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Outcomes of GLP-1 RA in Diabetes & CVD: What are the key opportunities for cardiology practice? - https://pace-cmelearninglab.coursepath.com/2624002/course-toc |
Diabetes & CVD: Time for a multifactorial approach |
1 |
17 Jan 2021 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Outcomes of GLP-1 RA in Diabetes & CVD: What are the key opportunities for cardiology practice? - https://pace-cmelearninglab.coursepath.com/2624002/course-toc |
GLP-1 receptor agonists: The cardiovascular benefits beyond glucose control |
0 |
17 Jan 2021 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Outcomes of GLP-1 RA in Diabetes & CVD: What are the key opportunities for cardiology practice? - https://pace-cmelearninglab.coursepath.com/2624002/course-toc |
Translating GLP-1 trial outcomes to cardiology practice: Which patients will benefit? |
0 |
17 Jan 2021 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies - https://academy1745879297.coursepath.com/my-courses |
PCSK9 inhibition & CV events: Review of recent and upcoming hard endpoint outcome trials |
1 |
25 Jan 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies - https://academy1745879297.coursepath.com/my-courses |
PCSK9 inhibition across a wide spectrum of patients: For whom is it efficacious? |
1 |
25 Jan 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies - https://academy1745879297.coursepath.com/my-courses |
Understanding new PCSK9 outcome data: From the LDL |
1 |
25 Jan 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Preventing cardiovascular disease in patients with T2DM - The role of GLP-1 RA - https://pace-cmelearninglab.coursepath.com/1772034/course-toc |
Diabetes: How to reduce risk from a cardiovascular perspective? |
0 |
23 Aug 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Preventing cardiovascular disease in patients with T2DM - The role of GLP-1 RA - https://pace-cmelearninglab.coursepath.com/1772034/course-toc |
Practical management of cardiovascular risk: Lessons from latest diabetes trials |
0 |
23 Aug 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Preventing cardiovascular disease in patients with T2DM - The role of GLP-1 RA - https://pace-cmelearninglab.coursepath.com/1772034/course-toc |
The cardiovascular challenge for primary care in diabetes |
1 |
23 Aug 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Pulmonary arterial hypertension - key questions addressed - https://pace-cmelearninglab.coursepath.com/1640962/course-toc |
Diagnosis, classification of patients, prognosis |
0 |
23 May 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Pulmonary arterial hypertension - key questions addressed - https://pace-cmelearninglab.coursepath.com/1640962/course-toc |
Future perspectives |
0 |
23 May 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Pulmonary arterial hypertension - key questions addressed - https://pace-cmelearninglab.coursepath.com/1640962/course-toc |
Treatment options, follow-up of non-responsive patients, optimization of therapy |
0 |
23 May 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Pulmonary arterial hypertension - key questions addressed - https://pace-cmelearninglab.coursepath.com/1640962/course-toc |
Underlying pathophysiology, characteristics, clinical subgroups, prevalence and risk factors |
1 |
23 May 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
SGLT2 Inhibition, Diabetes and CVD: Where does this fit in CV risk management? - https://academy1745879297.coursepath.com/my-courses |
Challenging CV risk in diabetes: Ready for a new approach? |
0 |
24 Jan 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
SGLT2 Inhibition, Diabetes and CVD: Where does this fit in CV risk management? - https://academy1745879297.coursepath.com/my-courses |
Heart failure & diabetes: SGLT2 inhibition, a paradigm shift? |
0 |
24 Jan 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
SGLT2 Inhibition, Diabetes and CVD: Where does this fit in CV risk management? - https://academy1745879297.coursepath.com/my-courses |
SGLT-2 inhibitors in T2DM Management: Current position & future promise |
0 |
24 Jan 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Targeting residual risk with anti-inflammatory therapies - https://pace-cmelearninglab.coursepath.com/1575426/course-toc |
Inflammation & CVD: Translating insights from vascular biology to the clinic |
0 |
07 May 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Targeting residual risk with anti-inflammatory therapies - https://pace-cmelearninglab.coursepath.com/1575426/course-toc |
The CANTOS trial: Implications for the management of patients with residual risk |
0 |
07 May 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Targeting residual risk with anti-inflammatory therapies - https://pace-cmelearninglab.coursepath.com/1575426/course-toc |
The new era of residual risk reduction |
0 |
07 May 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Targeting residual risk with anti-inflammatory therapies - https://pace-cmelearninglab.coursepath.com/1575426/course-toc |
The patient with inflammatory residual risk: Who is it? |
1 |
07 May 2020 |
|
EXCEMED |
| EXCEMED/ S. Taddei |
Interactive clinical case: Heart failure - https://www.excemed.org/user/login?destination=excemedlearning/67 |
Interactive clinical case: Heart failure |
1 |
20 Nov 2020 |
|
Maastricht University Medical Center |
| Maastricht University Medical Center/ H. Crijns |
Radcliffe CME - https://www.radcliffe-cme.com/user/login?destination=homepage |
Case study: Successful AF ablation program - perils, pitfalls and tricks |
0 |
17 May 2020 |
| Maastricht University Medical Center/ H. Crijns |
Radcliffe CME - https://www.radcliffe-cme.com/user/login?destination=homepage |
Introduction: What is the value of a multidisciplianry AF Heart Team? |
1 |
17 May 2020 |
| Maastricht University Medical Center/ H. Crijns |
Radcliffe CME - https://www.radcliffe-cme.com/user/login?destination=homepage |
What are the practical considerations for implementing a MDT Heart Team in your hospital? |
0 |
17 May 2020 |
| Maastricht University Medical Center/ H. Crijns |
Radcliffe CME - https://www.radcliffe-cme.com/user/login?destination=homepage |
What evidence exists to support hybrid ablation? |
0 |
17 May 2020 |
|
The University of Edinburgh |
| The University of Edinburgh/ K. Fox |
CV Risk Doesn't End in the Cath Lab: Event-Free Survival Is a Lasting Commitment - http://www.medscape.org |
CV Risk Doesn't End in the Cath Lab: Event-Free Survival Is a Lasting Commitment |
1 |
09 Dec 2019 |
| The University of Edinburgh/ K. Fox |
Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials - http://www.staging.medscape.org/viewarticle/876882 |
Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials |
1 |
28 May 2019 |
| The University of Edinburgh/ K. Fox |
Improving ACS Outcomes: Acute Treatment and Chronic Management - http://www.staging.medscape.org/viewarticle/882603 |
Improving ACS Outcomes: Acute Treatment and Chronic Management |
1 |
22 Aug 2019 |
|
UpToDate |
| UpToDate/ T. Post |
https://uptodate.com - https://www.uptodate.com |
UpToDate |
1 |
14 Mar 2020 |
| UpToDate/ T. Post |
UpToDate - https://www.uptodate.com |
UpToDate |
1 |
29 Jan 2021 |
